Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery
Authors:
- Stefania CosioSCStefania Cosio
- Valentina ZizioliVZValentina Zizioli
- Sara NotaroSNSara Notaro
- Roberta TanaRTRoberta Tana
- Andrea PanattoniAPAndrea Panattoni
- Enrico SartoriESEnrico Sartori
- 1 January 2017
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (1) , 28-36
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysisGynecologic Oncology, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian CancerObstetrics & Gynecology, 2006
- Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosisThe Lancet Oncology, 2002
- What Are the Current Surgical Objectives, Strategies, and Technical Capabilities of Gynecologic Oncologists Treating Advanced Epithelial Ovarian Cancer?Gynecologic Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Up date in the management of advanced ovarian carcinomaCritical Reviews in Oncology/Hematology, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996